Scarica l'app Stockscreener
43.81
9.80%
3.91
Pre-mercato:
42.53
-1.28
-2.92%
Precedente Chiudi:
$39.90
Aprire:
$40.18
Volume 24 ore:
811.97K
Relative Volume:
1.43
Capitalizzazione di mercato:
$2.17B
Reddito:
-
Utile/perdita netta:
$-105.43M
Rapporto P/E:
-18.90
EPS:
-2.3183
Flusso di cassa netto:
$-88.42M
1 W Prestazione:
+7.38%
1M Prestazione:
+24.18%
6M Prestazione:
+191.10%
1 anno Prestazione:
+265.39%
Intervallo 1D:
$39.84
$45.52
Intervallo di 1 settimana:
$37.55
$45.52
Portata 52W:
$5.485
$45.52
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
43.81 | 2.17B | 0 | -105.43M | -88.42M | -2.3183 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Piper Sandler | Overweight |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Momentum Shift: Will Oruka Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD - Investing.com
Aug Selloffs: Will Oruka Therapeutics Inc outperform tech stocksQuarterly Investment Review & AI Powered Market Entry Strategies - baoquankhu1.vn
Does Oruka’s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)? - Yahoo Finance Singapore
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US6876041087 - marketscreener.com
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | HQ1 | US6876041087 - marketscreener.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighStill a Buy? - MarketBeat
Does Oruka Therapeutics, Inc. (ORKA) have the potential to rally 41.51% as Wall Street analysts expect? - MSN
BTIG Reiterates Oruka Therapeutics (ORKA) Buy Recommendation - MSN
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock By Investing.com - Investing.com India
Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $16,313.50 in Stock - MarketBeat
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,641 Shares of Stock - MarketBeat
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $71,407.70 in Stock - MarketBeat
Agarwal Arjun, Oruka Therapeutics SVP, sells $16k in ORKA stock - Investing.com Canada
[Form 4] Oruka Therapeutics, Inc. Insider Trading Activity - Stock Titan
Does Oruka Therapeutics, Inc. (ORKA) Have a Chance to Surge 41.51% According to Wall Street Analysts’ Predictions? - Bitget
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect? - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $86.00 at Leerink Partners - Defense World
Is Oruka Therapeutics’ (ORKA) ESOP Shelf Registration Quietly Redefining Its Funding Playbook? - simplywall.st
Oruka Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oruka Therapeutics, Inc. $ORKA is Fairmount Funds Management LLC's 7th Largest Position - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at Wall Street Zen - MarketBeat
Commodore Capital LP Has $33.71 Million Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Braidwell LP Sells 142,492 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
BTIG Research Reaffirms “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Wedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Oruka Therapeutics stock hits 52-week high at 36.53 USD By Investing.com - Investing.com India
Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Barclays Raises Price Target for ORKA to $50, Maintains Overweig - GuruFocus
ORKA’s Recent Moves Signal Strategic Realignment Amid Market Shifts - timothysykes.com
Barclays Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $72.00 - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Given "Buy" Rating at BTIG Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week High on Strong Earnings - MarketBeat
Oruka Therapeutics stock hits 52-week high at 36.53 USD - Investing.com
BTIG reiterates Buy on Oruka Therapeutics stock, $73 target - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Receives "Outperform" Rating from Wedbush - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Earns "Buy" Rating from Guggenheim - MarketBeat
Assessing Oruka Therapeutics (ORKA) Valuation As ORKA-001 Moves Into Long Term Psoriasis Trial - Sahm
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Oruka Therapeutics (NASDAQ:ORKA) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oruka Therapeutics Inc Azioni (ORKA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Agarwal Arjun | Senior Vice President, Finance |
Mar 16 '26 |
Sale |
41.30 |
395 |
16,313 |
18,863 |
| Sandler Laura Lee | Chief Operating Officer |
Mar 16 '26 |
Sale |
41.30 |
600 |
24,780 |
236,984 |
| Goncalves Joana | Chief Medical Officer |
Mar 16 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
41,018 |
| Goncalves Joana | Chief Medical Officer |
Mar 16 '26 |
Sale |
40.91 |
7,641 |
312,560 |
33,377 |
| Quinlan Paul T | General Counsel |
Mar 16 '26 |
Sale |
41.30 |
733 |
30,273 |
31,767 |
| Sandler Laura Lee | Chief Operating Officer |
Mar 02 '26 |
Option Exercise |
7.80 |
5,000 |
39,000 |
242,584 |
| Sandler Laura Lee | Chief Operating Officer |
Mar 02 '26 |
Sale |
33.56 |
5,000 |
167,822 |
237,584 |
| Goncalves Joana | Chief Medical Officer |
Feb 17 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
41,018 |
| Goncalves Joana | Chief Medical Officer |
Feb 17 '26 |
Sale |
32.37 |
7,000 |
226,559 |
34,018 |
| Goncalves Joana | Chief Medical Officer |
Jan 15 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
8,518 |
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):